StockNews.com Downgrades Repligen (NASDAQ:RGEN) to Sell

Repligen (NASDAQ:RGEN) was downgraded by investment analysts at StockNews.com from a “hold” rating to a “sell” rating in a research report issued on Friday.

Other research analysts also recently issued research reports about the stock. Wolfe Research started coverage on shares of Repligen in a research note on Thursday, November 14th. They issued a “peer perform” rating for the company. TD Cowen initiated coverage on shares of Repligen in a research note on Monday, February 10th. They set a “buy” rating and a $200.00 price objective on the stock. Royal Bank of Canada lifted their target price on shares of Repligen from $203.00 to $205.00 and gave the stock an “outperform” rating in a research note on Friday. HC Wainwright reiterated a “buy” rating and issued a $180.00 price target on shares of Repligen in a report on Friday. Finally, Canaccord Genuity Group began coverage on Repligen in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective on the stock. One analyst has rated the stock with a sell rating, five have issued a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, Repligen currently has a consensus rating of “Moderate Buy” and an average target price of $181.00.

Repligen Trading Down 2.3 %

Shares of RGEN stock opened at $158.99 on Friday. Repligen has a fifty-two week low of $113.50 and a fifty-two week high of $203.13. The company has a 50 day moving average price of $155.22 and a 200 day moving average price of $148.68. The stock has a market capitalization of $8.91 billion, a P/E ratio of -311.75, a price-to-earnings-growth ratio of 4.54 and a beta of 0.99. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The company had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. Equities research analysts predict that Repligen will post 1.72 EPS for the current fiscal year.

Hedge Funds Weigh In On Repligen

Several hedge funds have recently bought and sold shares of RGEN. CWM LLC boosted its stake in Repligen by 36.3% during the 3rd quarter. CWM LLC now owns 428 shares of the biotechnology company’s stock valued at $64,000 after purchasing an additional 114 shares during the period. Creative Planning boosted its position in shares of Repligen by 32.6% in the third quarter. Creative Planning now owns 5,123 shares of the biotechnology company’s stock valued at $762,000 after acquiring an additional 1,259 shares during the period. Blue Trust Inc. boosted its position in shares of Repligen by 113.4% in the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock valued at $36,000 after acquiring an additional 127 shares during the period. Raymond James & Associates grew its stake in shares of Repligen by 49.3% in the third quarter. Raymond James & Associates now owns 82,277 shares of the biotechnology company’s stock worth $12,244,000 after acquiring an additional 27,158 shares during the last quarter. Finally, Greenleaf Trust bought a new position in Repligen during the third quarter worth $226,000. 97.64% of the stock is owned by institutional investors and hedge funds.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.